
CLAIMS:

1. Use of a compound according to Formula (Ia) or a pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof for the manufacture of medicament for the treatment of Primary Biliary Cirrhosis (PBC), Primary Sclerosing Cholangitis (PSC) or Inflammatory Bowel Disease (IBD), wherein the compound of Formula (Ia) is:



(Ia)

wherein:


Q is phenylene substituted with one chloro;

Y is N;

R^1 is cyclopropyl or methyl;

R^2 and R^3 are chloro;

R^4-A is:




,

wherein the pyridylene is optionally substituted with one or two groups independently selected from halogen, C_{1-4}-alkoxy, halo-C_{1-4}-alkoxy, C_{1-4}-alkyl, and halo-C_{1-4}-alkyl and R^4 is $-CO_2R^5$ or $-C(O)NR^5R^6$;

R^5 is hydrogen; and

R^6 is C_{1-2}-alkyl, optionally substituted $-SO_3H$, and $-CO_2H$.

2. Use of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof for the manufacture of medicament for the treatment of Primary Biliary Cirrhosis (PBC), Primary Sclerosing Cholangitis (PSC) or Inflammatory Bowel Disease (IBD), wherein the compound of Formula (Ia):



(Ia)

wherein:


Q is phenylene substituted with one chloro;

Y is N;

R^1 is cyclopropyl or methyl;

R^2 and R^3 are chloro;

R^4-A is:



,

wherein the pyridylene is optionally substituted with one or two groups independently selected from halogen, C_{1-4}-alkoxy, halo-C_{1-4}-alkoxy, C_{1-4}-alkyl, and halo-C_{1-4}-alkyl and R^4 is $-CO_2R^5$ or $-C(O)NR^5R^6$;

R^5 is hydrogen; and

R^6 is C_{1-2}-alkyl optionally substituted with $-CO_2H$ or $-SO_3H$.

3. The use of claim 1 or 2, wherein A is pyridylene substituted with one fluoro.

4. The use of claim 1 or 2, wherein A is unsubstituted pyridylene.

5. The use of any one of claims 1-3, wherein R^4 is $-CO_2R^5$.



6. The use of any one of claims 1-3 wherein:

R^4 is $-C(O)NR^5R^6$;





and

R^6 is C_{1-2}-alkyl, wherein said C_{1-2}-alkyl is substituted with $-SO_3H$ or $-CO_2H$.

7. The use of claim 1 or 2 wherein R^4-A is:






,
, or 
.

8. The use of claim 1, wherein the compound of Formula (Ia) is selected from the group consisting of:


, 
, 
, and 
;


or pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof.

9. The use of claim 2, wherein the compound of Formula (Ia) is selected from the group consisting of:


,

,

, and

;


or pharmaceutically acceptable salt thereof.

10. The use of claim 1 or 2 wherein the compound of Formala (Ia) has the following formula:


;

or a pharmaceutically acceptable salt thereof.

11. The use of claim 1 or 2 wherein the compound of Formula (Ia) has the following formula:


F
O
OH
HO
N
N
O
O
N
Cl
Cl
Cl
F

.